Department of Surgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York.
Center for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, New York.
Shock. 2022 Feb 1;57(2):246-255. doi: 10.1097/SHK.0000000000001894.
Triggering receptor expressed on myeloid cells-1 (TREM-1) has important implications in sepsis and inflammation and is a novel receptor for extracellular cold-inducible RNA-binding protein (eCIRP). We hypothesize that the inhibition of TREM-1 via its interaction with eCIRP by novel peptide inhibitor M3 or knockout gene will attenuate the inflammation and injury associated with severe hepatic ischemia/reperfusion (I/R).
Wild-type (WT) C57BL/6 and TREM-1-/- mice underwent 60 min of 70% hepatic ischemia, with 24 h of reperfusion. Additionally, WT mice underwent hepatic I/R and were treated with M3 (10 mg/kg body weight) or vehicle (normal saline) at the start of reperfusion. Blood and ischemic liver tissues were collected, and analysis was performed using enzymatic assays, enzyme-linked immunosorbent assay, reverse-transcription quantitative polymerase chain reaction, and pathohistology techniques. For survival surgery, mice additionally underwent resection of non-ischemic lobes of the liver and survival was monitored for 10 days.
There was an increase in serum levels of tissue markers including aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase as well as cytokine levels (IL-6) and histological scoring of hematoxylin and eosin sections in WT I/R mice. These markers decreased substantially in TREM-1-/- mice. Additionally, neutrophil infiltration markers and markers of local inflammation (myeloperoxidase, macrophage inflammatory protein-2, cyclooxygenase-2) were attenuated in TREM-1-/- mice. Similarly, we show a significant decrease in injury and inflammation markers with M3 treatment. Additionally, we demonstrate decreased apoptosis with TREM-1 inhibition. Finally, M3 treatment improved the survival rate from 42% to 75% after hepatic I/R.
TREM-1 is an important eCIRP receptor in the inflammatory response of hepatic I/R, and deficiency of TREM-1 via knockout gene or peptide inhibition attenuated liver injury and inflammation, and improved survival. Inhibition of the TREM-1 and eCIRP interaction in hepatic I/R may have important therapeutic potential.
髓样细胞表达的触发受体-1(TREM-1)在脓毒症和炎症中具有重要意义,是细胞外冷诱导 RNA 结合蛋白(eCIRP)的新型受体。我们假设通过新型肽抑制剂 M3 或基因敲除来抑制 TREM-1 与其相互作用,将减轻严重肝缺血/再灌注(I/R)相关的炎症和损伤。
野生型(WT)C57BL/6 和 TREM-1-/- 小鼠接受 70%肝缺血 60 分钟,再灌注 24 小时。此外,WT 小鼠接受肝 I/R,并在再灌注开始时用 M3(10mg/kg 体重)或载体(生理盐水)治疗。采集血液和缺血肝组织,并用酶法测定、酶联免疫吸附试验、逆转录定量聚合酶链反应和病理组织学技术进行分析。对于生存手术,小鼠还切除了非缺血肝叶,并监测 10 天的生存情况。
WT I/R 小鼠血清组织标志物(包括天冬氨酸转氨酶、丙氨酸转氨酶和乳酸脱氢酶)和细胞因子水平(IL-6)以及苏木精和伊红切片的组织学评分均升高。这些标志物在 TREM-1-/- 小鼠中显著降低。此外,TREM-1-/- 小鼠中性粒细胞浸润标志物和局部炎症标志物(髓过氧化物酶、巨噬细胞炎症蛋白-2、环氧化酶-2)减少。同样,我们发现 M3 治疗后损伤和炎症标志物显著减少。此外,我们证明 TREM-1 抑制可减少细胞凋亡。最后,M3 治疗使肝 I/R 后的存活率从 42%提高到 75%。
TREM-1 是肝 I/R 炎症反应中 eCIRP 的重要受体,通过基因敲除或肽抑制缺乏 TREM-1 可减轻肝损伤和炎症,提高生存率。在肝 I/R 中抑制 TREM-1 和 eCIRP 相互作用可能具有重要的治疗潜力。